All In Biotech

Drug Trial Radar · NCT01443858

Meclizine as a Potential Smoking Cessation Treatment

Last checked: Nov 20, 2026Latest source record: Aug 1, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 146 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

146

Actual

Start

Aug 2011

Primary completion

Dec 2012

Study completion Jul 2013

Sponsor

Lead sponsor
Duke UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Philip Morris USA, Inc.
First posted
Sep 30, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate whether meclizine, an antihistamine used to prevent or treat motion sickness, can help smokers quit smoking. This study will also investigate the potential relationship between genes you have inherited and success in quitting smoking.

Conditions

  • Smoking Cessation

Interventions

  • MeclizineDrug

    Pre-Quit Period: In this group, participants will take meclizine daily during the three week pre-quit period. The meclizine will be taken in two doses daily, one capsule with breakfast and one with dinner.

  • Nicotine PatchDrug

    Pre-Quit Period: During weeks two and three, participants will apply active 21mg/24h nicotine patches daily. Post-Quit Period: Following the quit-day these participants will apply active nicotine patches daily using the following dose schedule: 21mg/24h for four weeks, 14mg/24h for one week, and 7mg/24h for one week.

  • PlaceboDrug

    Pre-Quit Period: In this group, participants will take placebo capsules daily during the three week pre-quit period. The placebo will be taken in two doses daily, one capsule with breakfast and one with dinner.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Change in Expired Air Carbon Monoxide (CO) at End of Week 1Time frame: After 1 week of treatment (relative to baseline)
  2. Percentage of Change in Expired Air Carbon Monoxide (CO) at End of Week 3Time frame: After 3 weeks of treatment (relative to baseline)

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Duke Center for Nicotine and Smoking Cessation Research

    Charlotte, North Carolina

  • Duke Center for Nicotine and Smoking Cessation Research

    Durham, North Carolina

  • Duke Center for Nicotine and Smoking Cessation Research

    Raleigh, North Carolina

  • Duke Center for Nicotine and Smoking Cessation Research

    Winston-Salem, North Carolina

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.